



ASX ANNOUNCEMENT

31 July 2020

**Company Announcements Office
ASX Limited
Exchange Centre
20 Bridge Street
SYDNEY NSW 2000**

Dear Sir / Madam,

Notification under sections 708A(5)(e) and (6) of the Corporations Act 2001 (Cth)

CardieX has issued two Appendix 2A's with respect to the issue of 83,333,334 ordinary shares (CDX) and 16,666,666 listed CDXO options of the Company. Details of the Placement are set out in the announcement of 27 July 2020.

CardieX gives notice under section 708A(5)(e) of the Corporations Act 2001 (Cth) that:

1. Under the Placement, CardieX has issued 83,333,334 ordinary shares (CDX) at the issue price of \$0.03 per share and 16,666,666 free 1 for 5 attaching listed options (CDXO), raising \$2,500,000 without disclosure to investors under Part 6D.2 of the Corporations Act; and
2. As at the date of this notice:
 - (a) CardieX has complied with the provisions of Chapter 2M of the Act;
 - (b) CardieX has complied with section 674 of the Act; and
 - (c) there is no "excluded information" within the meaning of sections 708A(7) and 708A(8) of the Act which is required to be disclosed under section 708A(6)(e) of the Act.

Authorised for release by the Board of Directors.

For further information please contact:

**Jarrold White
Director**

About CardieX

CardieX is a global health technology company that develops digital and device-based solutions for large-scale population health disorders. The Company's XCEL device (developed & marketed by 100% subsidiary ATCOR) is the world leader in measuring "central blood pressure" which is considered essential for the management of hypertension and related cardiovascular disorders.